AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
AEON Biopharma announced expanded structural data demonstrating molecular similarity of its biosimilar candidate ABP-450 to the reference product BOTOX®. The company reported 98% sequence coverage with 100% amino acid identity and identical disulfide bond connectivity critical for toxin activation. Positive feedback from the FDA on the analytical s…